Target Name: RFC2
NCBI ID: G5982
Review Report on RFC2 Target / Biomarker Content of Review Report on RFC2 Target / Biomarker
RFC2
Other Name(s): RF-C 40 kDa subunit | replication factor C subunit 2 | activator 1 subunit 2 | Activator 1 40 kDa subunit | Replication factor C subunit 2, transcript variant 2 | A1 | RFC2 variant 2 | MGC3665 | RFC2_HUMAN | A1 40 kDa subunit | Replication factor C subunit 2 (isoform 1) | RFC2 variant 1 | Activator 1 | RFC40 | replication factor C (activator 1) 2, 40kDa | Replication factor C subunit 2, transcript variant 1 | Replication factor C subunit 2 | Replication factor C 40 kDa subunit | Replication factor C subunit 2 (isoform 2) | Activator 1 subunit 2

Understanding The RFC2 Protein: Potential Drug Targets

The RFC2 (RF-C 40 kDa subunit) is a protein that is expressed in human tissues and is known for its role in the immune response. The RFC2 protein has been identified as a potential drug target and has been shown to play a role in a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In this article, we will explore the biology and potential drug targets of the RFC2 protein.

The RFC2 protein

The RFC2 protein is a member of the heat shock protein (HSP) family and is expressed in a variety of tissues, including muscle, pancreas, and brain. It is made up of 40 kDa and has a calculated molecular weight of 43.8 kDa. The RFC2 protein is highly conserved and has a single known function, which is to form the nucleosome in the DNA double helix.

The nucleosome is the basic unit of DNA, and it is a complex structure that consists of a protein core and a DNA molecule. The RFC2 protein forms the nucleosome by repeating a specific sequence of amino acids, which is similar to that of histone H3. The RFC2 protein is able to form stable nucleosomes that are resistant to various forms of stress, such as temperature, pH, and radiation. This ability to form stable nucleosomes makes the RFC2 protein an important player in the immune response and a potential drug target.

Potential drug targets

The RFC2 protein has been identified as a potential drug target due to its role in a variety of diseases. One of the main reasons for its potential as a drug target is its involvement in cancer. Cancer is a disease that is characterized by the formation of tumors, which can be caused by a variety of factors, including mutations, errors in gene expression, and inflammation. The RFC2 protein has been shown to play a role in the regulation of cell division and has been linked to the development and progression of a variety of cancers.

In addition to its role in cancer, the RFC2 protein is also potential drug targets for other diseases, including autoimmune disorders and neurodegenerative diseases. The RFC2 protein has been shown to be involved in the regulation of immune responses and has been linked to the development of autoimmune disorders. Additionally, the RFC2 protein has also been shown to play a role in the regulation of neurotransmitter release and has been linked to the development of neurodegenerative diseases.

Conclusion

In conclusion, the RFC2 protein is a complex protein that is expressed in a variety of tissues and is known for its role in the immune response. The RFC2 protein has been identified as a potential drug target due to its involvement in a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Further research is needed to fully understand the biology and potential drug targets of the RFC2 protein.

Protein Name: Replication Factor C Subunit 2

Functions: The elongation of primed DNA templates by DNA polymerase delta and epsilon requires the action of the accessory proteins proliferating cell nuclear antigen (PCNA) and activator 1. This subunit binds ATP (By similarity)

The "RFC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RFC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RFC3 | RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP | RGSL1 | RHAG | RHBDD1 | RHBDD2 | RHBDD3 | RHBDF1 | RHBDF2 | RHBDL1 | RHBDL2 | RHBDL3 | RHBG | RHCE | RHCG | RHD | RHEB | RHEBL1 | RHEBP1 | RHEX | RHNO1 | RHO | Rho GTPase | Rho kinase (ROCK) | RHOA